Terms: = Liver cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Prognosis
72 results:
1. let-7g sensitized liver cancer cells to 5-fluorouracil by downregulating ABCC10 expression.
Chen Y; Zhang B; Zhong C; Zhou Y; Xue L; Luo C; Yi L; Gong Q; Long Y
Chem Biol Drug Des; 2024 Jan; 103(1):e14396. PubMed ID: 38054583
[TBL] [Abstract] [Full Text] [Related]
2. Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast cancer: A Retrospective Analysis of the MONARCH 2 Trial.
Gerratana L; Kocherginsky M; Davis AA; D'Amico P; Reduzzi C; Puglisi F; Cristofanilli M
Oncologist; 2024 Feb; 29(2):123-131. PubMed ID: 37935631
[TBL] [Abstract] [Full Text] [Related]
3. Integrated analysis and validation of the TRIM28-H2AX-cdk4 diagnostic model assists to predict the progression of HCC.
Tian Q; Lu G; Ma Y; Ma L; Shang Y; Guo N; Huang Y; Zhu L; Du R
Aging (Albany NY); 2023 Oct; 15(24):14617-14650. PubMed ID: 37870748
[TBL] [Abstract] [Full Text] [Related]
4. TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways.
Zhang Y; Wang ZZ; Han AQ; Yang MY; Zhu LX; Pan FM; Wang Y
Hepatobiliary Pancreat Dis Int; 2024 Apr; 23(2):195-209. PubMed ID: 37806848
[TBL] [Abstract] [Full Text] [Related]
5. Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report.
Yoneto T; Hasumi K; Takahashi N; Seki N; Takeda Y; Yoshimoto T
J Med Case Rep; 2023 May; 17(1):190. PubMed ID: 37158934
[TBL] [Abstract] [Full Text] [Related]
6. [Treatment of palbociclib in hormone receptor positive breast cancer: a real-world study and efficacy prediction model].
Yang YQ; Sun CX; Huang X; Li W; Yin YM
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):348-357. PubMed ID: 37078217
[No Abstract] [Full Text] [Related]
7. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.
Liu Y; Ma J; Wang X; Liu P; Cai C; Han Y; Zeng S; Feng Z; Shen H
Comput Biol Med; 2023 May; 158():106862. PubMed ID: 37044053
[TBL] [Abstract] [Full Text] [Related]
8. Identification of prognosis-related cyclin-dependent kinases and potential response drugs in hepatocellular carcinoma.
Chen S; Shen B; Wu Y; Shen L; Qi H; Cao F; Huang T; Tan H; Zhang G; Fan W
J Cancer Res Ther; 2023 Feb; 19(1):108-116. PubMed ID: 37006050
[TBL] [Abstract] [Full Text] [Related]
9. Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma.
Jiang C; Liu Z; Yuan J; Wu Z; Kong L; Yang J; Lv T
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901767
[TBL] [Abstract] [Full Text] [Related]
10. [Eight Cases of Breast cancer That Relapsed More Than Ten Years after Initial Treatment].
Yoshimura A; Ueda T; Tanaka T; Kirihataya Y; Soga M; Yokotani T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1935-1937. PubMed ID: 36733049
[TBL] [Abstract] [Full Text] [Related]
11. Tumor-suppressive role of microfibrillar associated protein 4 and its clinical significance as prognostic factor and diagnostic biomarker in hepatocellular carcinoma.
Li J; Wang J; Liu Z; Guo H; Wei X; Wei Q; Zheng S; Xu X
J Cancer Res Ther; 2022 Dec; 18(7):1919-1925. PubMed ID: 36647950
[TBL] [Abstract] [Full Text] [Related]
12. Exploring the mechanisms underlying the therapeutic effect of the
Qing L; Pan B; He Y; Liu Y; Zhao M; Niu B; Gao X
Aging (Albany NY); 2022 Nov; 14(22):9103-9127. PubMed ID: 36403263
[TBL] [Abstract] [Full Text] [Related]
13. Identification and Analysis of Immune-Related Gene Signature in Hepatocellular Carcinoma.
Shen B; Zhang G; Liu Y; Wang J; Jiang J
Genes (Basel); 2022 Oct; 13(10):. PubMed ID: 36292719
[TBL] [Abstract] [Full Text] [Related]
14. ATP13A2 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.
Huang J; Xu S; Yu Z; Zheng Y; Yang B; Ou Q
J Gastrointest Surg; 2023 Jan; 27(1):56-66. PubMed ID: 36127552
[TBL] [Abstract] [Full Text] [Related]
15. Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates.
Guo C; Tang Y; Yang Z; Li G; Zhang Y
Front Immunol; 2022; 13():958161. PubMed ID: 36032071
[TBL] [Abstract] [Full Text] [Related]
16. High expression of serine and arginine-rich splicing factor 9 (SRSF9) is associated with hepatocellular carcinoma progression and a poor prognosis.
Zhang G; Liu B; Shang H; Wu G; Wu D; Wang L; Li S; Wang Z; Wang S; Yuan J
BMC Med Genomics; 2022 Aug; 15(1):180. PubMed ID: 35971121
[TBL] [Abstract] [Full Text] [Related]
17. RNF2 mediates pulmonary fibroblasts activation and proliferation by regulating mTOR and p16-cdk4-Rb1 signaling pathway.
Pan L; Hu Y; Qian C; Yao Y; Wang S; Shi W; Xu T
Inflamm Res; 2022 Nov; 71(10-11):1283-1303. PubMed ID: 35933565
[TBL] [Abstract] [Full Text] [Related]
18. LncRNA UBE2R2-AS1, as prognostic marker, promotes cell proliferation and EMT in prostate cancer.
Wang F; Zhao M; Jiang Y; Xia S; Sun D; Zhou D; Dong Z
Histol Histopathol; 2023 Jun; 38(6):637-645. PubMed ID: 35916204
[TBL] [Abstract] [Full Text] [Related]
19. ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma.
Wang Y; Zhang Y; Mi J; Jiang C; Wang Q; Li X; Zhao M; Geng Z; Song X; Li J; Zuo L; Ge S; Zhang Z; Wen H; Wang Z; Su F
Oncogene; 2022 Jul; 41(29):3680-3693. PubMed ID: 35725908
[TBL] [Abstract] [Full Text] [Related]
20. Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.
Wang J; Liu X; Chu H; Chen J
PeerJ; 2022; 10():e13535. PubMed ID: 35694386
[TBL] [Abstract] [Full Text] [Related]
[Next]
